BOSTON and WUHAN, China, May 11, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., a clinical-stage biotechnology company discovering and developing innovative therapies for ocular and other genetic disease, today announced that the results of two clinical studies utilizing NFS-01 (rAAV2-ND4) in the treatment of Leber's Hereditary Optic Neuropathy (LHON) will be presented in May 2020 at the American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting and the Association for Vision and Ophthalmology (ARVO) Annual Meeting.
Founder Bin Li, M.D., Ph.D., professor of ophthalmology at the Tongji Medical College of Huazhong University of Science and Technology (HUST), initiated the first China gene therapy clinical trial in 2011, evaluating an adeno-associated virus serotype 2 (AAV2)-based gene therapy in nine Leber's Hereditary Optic Neuropathy (LHON) patients with the G11778A (ND4) mutation. Patients have been followed for over 7 years, several demonstrating significant visual acuity improvement and none reporting severe adverse events.
"The exciting results of the first study (NCT01267422) have been instrumental in developing the largest international clinical study (NCT03153293) in 159 LHON patients, who have been followed for 12 months," said Alvin Luk, Ph.D., M.B.A., C.C.R.A., Chief Executive Officer of Neurophth. "Our results from NFS-01 demonstrate the potential of gene therapy to be both effective and safe for the treatment of LHON and further validate Neurophth's platform which is being applied across a growing pipeline of pre-clinical and clinical programs in gene therapy to treat a wide range of inherited diseases."
ASGCT: American Society of Gene and Cell Therapy Virtual Annual Meeting 2020Presentations can be accessed through ASGCT's website at http://www.asgct.org on May 12, 2020.
First China International Gene Therapy Study in Leber's Hereditary Optic Neuropathy (Abstract #1307)Oral presentation by Alvin Luk, Ph.D., M.B.A., C.C.R.A., Chief Executive Officer, Neurophth Session Date/Time: Friday, May 15, 10:45AM EDTSession Title:AAV Vectors - Clinical Studies I
Multiyear Follow-up of AAV2-ND4 Gene Therapy for Leber's Hereditary Optic Neuropathy (Abstract #621)Poster presentation by Su Xiao, Ph.D., Co-Founder and Chief Technical Operations Officer, NeurophthSession Date/Time: Wednesday, May 13, 5:30PM EDTSession Title:AAV Vectors - Clinical Studies
ARVO: Association for Vision and Ophthalmology The ARVO 2020 Annual Meeting has been modified to a virtual format and presentations have been published online on May 6, 2020.
First China International Gene Therapy Study in Leber's Hereditary Optic Neuropathy (Abstract #5182)Oral Presentation by Alvin Luk, Ph.D., M.B.A., C.C.R.A., Chief Executive Officer, NeurophthNarrated presentation will be available onlineScientific Section: Eye Movements/Strabismus/Amblyopia/Neuro-Ophthalmology
About Neurophth Therapeutics, Inc.
Neurophth Therapeutics, Inc. ("Neurophth") is China's first gene therapy company for ophthalmic diseases. Founded in 2016 by Professor Bin Li, M.D., Ph.D., the clinical-stage biotechnology company is dedicated to discovering and developing gene therapies for ocular and other genetic diseases. Currently, Neurophth is advancing several clinical-stage and pre-clinical programs in ophthalmology. In April 2020, Neurophth successfully raised $18.4 million USD in a Series A round led by Fosun's InnoStar Venture and Sequoia Capital China. The company plans to bring the lead assets to patients globally and build a GMP gene therapy manufacturing facility for global supply.
About NFS-01
NFS-01 is an AAV construct comprising with promoter, mitochondrial targeting sequence (MTS), correct ND4 gene sequence, and an untranslated region flanked by two inverted terminal repeats (ITRs). In 2011, Neurophth initiated the world's first investigational NFS-01 (AAV2-ND4) gene therapy study (NCT01267422) of a single intravitreal injection into one of the eyes of patient with ND4 mutation associated with Leber's Hereditary Optic Neuropathy (LHON). The corrected ND4 gene is transferred into the cell to be expressed and eventually produces the missing functional protein to restore mitochondrial function of the respiratory chain. After nearly 8 years of long-term follow-up, the treatment displayed good safety profiles and patients have maintained significant visual acuity improvement to-date. These results demonstrated long-term safety and durability of clinical application of gene therapy technology and were published in Ophthalmology 2020. Encouraged by these results, Professor Li's team has completed an international gene therapy clinical trial (NCT03153293) during 2017-2018 in 159 LHON patients in China and Argentina, which is the world's largest clinical trial for LHON gene therapy.
About Leber's Hereditary Optic Neuropathy (LHON)
Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited mitochondrial disorder which often manifests as bilateral visual loss. The most common mutation is the mitochondrial DNA at nucleotide position of 11778G>A, which is located within the NADH ubiquinone oxidoreductase subunit-4 (ND4) gene. This mutation causes impairment of the respiratory chain, adenosine triphosphate deficiency, and oxidative stress in retinal ganglion cells, leading to apoptosis. There is currently no effective treatment or cure for LHON.
SOURCE Neurophth Therapeutics, Inc.
More:
Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings - PRNewswire
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]